Otologic Pharmaceutics

Otologic Pharmaceutics was founded in 2009, with the mission of developing treatments for hearing loss, including acute hearing loss, noise induced hearing loss and Cisplatin induced hearing loss. Its current lead product candidate is NHPN-1010. In collaboration with the Hough Ear Institute and Oklahoma Medical Research Foundation they will evaluate the potential of using NHPN-1010 to treat tinnitus.

Clinical Trials — Completed

Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC

Condition: Hearing Loss; Sensorineural Hearing Loss; Noise-Induced Hearing Loss
Intervention: Drug: HPN-07; Drug: NAC; Drug: Placebo
Phase: Phase 1

RECENT NEWS ON OTOLOGIC PHARMACEUTICS

Nothing Found

Sorry, no posts matched your criteria

COMPANY OVERVIEW

Otologic Pharmaceutics

Locations: United States
Year Founded: 2009
CEO: Clayton I. Duncan (MBA, MA)